FDA Grants Priority Review to Genentech ’s Baloxavir Marboxil for the Treatment of Influenza
South San Francisco, CA -- June 25, 2018 -- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has accepted a New Drug Application (NDA) and granted Priority Review...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials
More News: Clinical Trials | Food and Drug Administration (FDA) | Grants | Influenza | New Drug Applications | Pharmaceuticals